3,107 reports of this reaction
2.0% of all PEMBROLIZUMAB reports
#10 most reported adverse reaction
DECREASED APPETITE is the #10 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 3,107 FDA adverse event reports linking PEMBROLIZUMAB to DECREASED APPETITE. This represents approximately 2.0% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience decreased appetite should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DECREASED APPETITE is a less commonly reported adverse event for PEMBROLIZUMAB, but still significant enough to appear in the safety profile.
In addition to decreased appetite, the following adverse reactions have been reported for PEMBROLIZUMAB:
The following drugs have also been linked to decreased appetite in FDA adverse event reports:
DECREASED APPETITE has been reported as an adverse event in 3,107 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DECREASED APPETITE accounts for approximately 2.0% of all adverse event reports for PEMBROLIZUMAB, making it a notable side effect.
If you experience decreased appetite while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.